​

Ginkgo Bioworks (DNA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DNA Stock Forecast

Ginkgo Bioworks (DNA) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $7.34, with a high of $12.00 and a low of $4.35. This represents a -6.50% decline from the last price of $7.85.

- $3 $6 $9 $12 $15 High: $12 Avg: $7.34 Low: $4.35 Last Closed Price: $7.85

DNA Stock Rating

Ginkgo Bioworks stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (62.50%), 1 Hold (12.50%), 2 Sell (25.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 2 1 5 Strong Sell Sell Hold Buy Strong Buy

DNA Price Target Upside V Benchmarks

TypeNameUpside
StockGinkgo Bioworks-6.50%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$7.00
Last Closing Price$7.85$7.85$7.85
Upside/Downside---10.83%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25-11136
Mar, 25-11136
Feb, 25-11136
Jan, 25-11136
Dec, 24-11136
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 23, 2024Mark MassaroBTIG$7.00$8.30-15.66%-10.83%
Nov 29, 2022Berenberg Bank$6.00$1.84226.09%-23.57%
Aug 16, 2022BTIG$6.00$3.7460.43%-23.57%
Jun 16, 2022Jefferies$4.35$2.5967.95%-44.59%
Mar 03, 2022Steven MahCowen & Co.$12.00$3.86210.88%52.87%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 17, 2024Cowen & Co.BuyBuyhold
Aug 23, 2024BTIGSellSellhold
Jun 26, 2024BTIGSellSellhold
May 15, 2024BTIGBuySelldowngrade
May 10, 2024William BlairUnderperformdowngrade
Aug 16, 2022Raymond JamesOutperformOutperformhold
Aug 16, 2022BTIGBuyBuyhold
Aug 16, 2022CLSASelldowngrade
Jun 16, 2022JefferiesBuyBuyhold
May 18, 2022Bank of America SecuritiesUnderperformdowngrade

Financial Forecast

EPS Forecast

$-60 $-48 $-36 $-24 $-12 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-53.83$-50.15$-18.37$-10.54----
Avg Forecast$-7.90$-55.63$-17.60$-10.08$-5.81$-3.36$-4.14$-3.33
High Forecast$-7.38$-53.75$-16.80$-9.59$-4.33$-2.52$-3.94$-3.17
Low Forecast$-8.35$-57.89$-18.80$-10.65$-7.28$-4.25$-4.37$-3.52
Surprise %581.39%-9.85%4.38%4.56%----

Revenue Forecast

$200M $260M $320M $380M $440M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$313.84M$477.71M$251.46M$227.04M----
Avg Forecast$251.52M$471.16M$258.72M$227.75M$203.81M$246.09M$332.30M$396.40M
High Forecast$262.48M$485.92M$259.77M$227.86M$205.13M$246.09M$346.64M$413.50M
Low Forecast$238.79M$458.90M$257.68M$227.63M$202.49M$246.09M$319.94M$381.65M
Surprise %24.78%1.39%-2.81%-0.31%----

Net Income Forecast

$-3B $-2B $-2B $-1B $-600M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.83B$-2.10B$-892.87M$-547.03M----
Avg Forecast$-384.02M$-2.70B$-892.87M$-491.88M$-308.02M$-188.72M$-201.25M$-161.87M
High Forecast$-358.76M$-2.61B$-816.66M$-466.29M$-210.29M$-122.50M$-191.51M$-154.04M
Low Forecast$-405.79M$-2.81B$-913.88M$-517.47M$-354.09M$-206.59M$-212.53M$-170.95M
Surprise %376.55%-22.16%-11.21%----

DNA Forecast FAQ

Is Ginkgo Bioworks stock a buy?

Ginkgo Bioworks stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 1 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Ginkgo Bioworks is a favorable investment for most analysts.

What is Ginkgo Bioworks's price target?

Ginkgo Bioworks's price target, set by 8 Wall Street analysts, averages $7.34 over the next 12 months. The price target range spans from $4.35 at the low end to $12 at the high end, suggesting a potential -6.50% change from the previous closing price of $7.85.

How does Ginkgo Bioworks stock forecast compare to its benchmarks?

Ginkgo Bioworks's stock forecast shows a -6.50% downside, underperforming the average forecast for the healthcare stocks sector (35.94%) and underperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Ginkgo Bioworks over the past three months?

  • April 2025: 0% Strong Buy, 16.67% Buy, 16.67% Hold, 16.67% Sell, 50.00% Strong Sell.
  • March 2025: 0% Strong Buy, 16.67% Buy, 16.67% Hold, 16.67% Sell, 50.00% Strong Sell.
  • February 2025: 0% Strong Buy, 16.67% Buy, 16.67% Hold, 16.67% Sell, 50.00% Strong Sell.

What is Ginkgo Bioworks’s EPS forecast?

Ginkgo Bioworks's average annual EPS forecast for its fiscal year ending in December 2025 is $-5.81, marking a -44.88% decrease from the reported $-10.54 in 2024. Estimates for the following years are $-3.36 in 2026, $-4.14 in 2027, and $-3.33 in 2028.

What is Ginkgo Bioworks’s revenue forecast?

Ginkgo Bioworks's average annual revenue forecast for its fiscal year ending in December 2025 is $203.81M, reflecting a -10.23% decrease from the reported $227.04M in 2024. The forecast for 2026 is $246.09M, followed by $332.3M for 2027, and $396.4M for 2028.

What is Ginkgo Bioworks’s net income forecast?

Ginkgo Bioworks's net income forecast for the fiscal year ending in December 2025 stands at $-308M, representing a -43.69% decrease from the reported $-547M in 2024. Projections indicate $-189M in 2026, $-201M in 2027, and $-162M in 2028.